01 Single-Use TFF Is Expanding from Development to Commercial Manufacturing The Tangential Flow Filtration Market is shifting toward single-use systems that can support processes from laboratory development through commercial biomanufacturing. Disposable flow paths reduce cleaning requirements and help manufacturers change products more quickly, which is valuable in flexible multiproduct facilities. Suppliers are also expanding membrane areas, automation, sensors, and closed processing to make single-use TFF suitable for larger batches. This trend is changing TFF from mainly reusable stainless-steel equipment toward modular platforms that can be configured for different production scales. The approach supports faster facility setup and reduces cross-contamination concerns, increasing demand for disposable cassettes, hollow fibers, tubing assemblies, sensors, and automated filtration systems. In September 2025, Sartorius showcased large-scale single-use TFF technology supporting multi-modality biomanufacturing, with its portfolio spanning systems from development scale to commercial production.
01 Expansion of Advanced Biologics Is Increasing Downstream Filtration Demand Growth in monoclonal antibodies, gene therapies, vaccines, and other biologics is driving demand for scalable downstream filtration. TFF is widely suited to concentration and buffer exchange of proteins, viruses, nucleic acids, and other biological materials, making it useful across multiple therapeutic platforms. As more advanced therapies progress toward commercialization, manufacturers need filtration processes that can preserve sensitive molecules while delivering repeatable product concentration and purification. This creates demand for hollow-fiber modules, ultrafiltration cassettes, automated systems, and process-development equipment. Increasing biopharmaceutical manufacturing investment further supports this requirement because new capacity needs downstream operations capable of handling both established antibody products and emerging therapeutic modalities.
01 Membrane Fouling and Process Optimization Limit Filtration Efficiency TFF performance depends heavily on membrane selection and operating conditions, creating technical barriers to straightforward adoption. Proteins and other feed components can accumulate near the membrane surface and form a concentration or gel layer, reducing filtration efficiency. Developers must carefully optimize transmembrane pressure, crossflow rate, membrane cut-off, concentration factor, and diafiltration conditions for each product. Excessive pressure or unsuitable flow can reduce flux or affect sensitive biological materials. This means a TFF process developed for one molecule cannot always be transferred directly to another. Additional development experiments, specialized equipment, and technical expertise increase time and cost, particularly for smaller biotechnology companies with limited process-development resources.
01 Cell and Gene Therapies Create Demand for Gentle Hollow-Fiber TFF Cell and gene therapy manufacturing creates an opportunity for TFF suppliers because viral vectors, nucleic acids, and other sensitive biological materials require controlled concentration and buffer exchange. Hollow-fiber TFF offers a linear flow path that can support gentler processing of shear-sensitive products. Suppliers can capture this opportunity by providing membranes with different pore sizes, scalable modules, closed single-use systems, and equipment suitable for development through manufacturing. Regulatory progress in gene therapy also strengthens the need for reliable manufacturing technologies. As more developers move products from clinical research toward licensed production, demand should increase for filtration platforms that combine scalability, product recovery, process control, and compatibility with sensitive advanced-therapy materials.
01 Scaling TFF Without Changing Product Quality Remains Difficult Moving a TFF process from laboratory experiments to commercial manufacturing requires more than simply increasing membrane area. Manufacturers must maintain comparable flow conditions, transmembrane pressure, product concentration, membrane performance, and recovery as batch volumes increase. Large systems also introduce challenges involving minimum recirculation volume, sensor accuracy, automation, tubing configuration, and process control. These issues are particularly important in regulated biopharmaceutical manufacturing, where process changes must be understood and controlled. Suppliers therefore need scalable equipment families that reproduce important operating conditions from development through production. Successful scale-up depends on combining appropriate membrane selection with validated process parameters rather than relying only on larger filtration hardware.
September 2025 Repligen expanded its bioprocessing portfolio by advancing TFF solutions, including hollow fiber and membrane technologies, for pharmaceutical and biotechnology applications. The company focused on improving productivity and process optimization.
July 2025 Danaher expanded its bioprocessing capabilities through advancements in TFF technologies under its Cytiva business. The developments focused on improving purification workflows, reducing processing time, and supporting next-generation biologics production.
June 2025 Merck KGaA expanded its TFF solutions by introducing enhanced membrane filtration technologies and integrated bioprocessing systems. The company focused on supporting monoclonal antibody, vaccine, and cell and gene therapy manufacturing.
May 2025 Sartorius expanded its tangential flow filtration (TFF) portfolio by advancing single-use filtration technologies and bioprocessing solutions for biologics manufacturing. The developments focused on improving scalability, efficiency, and process flexibility in pharmaceutical production.